Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ABBV-399 · 1 trial · 1 indication
AUC (0-t) is defined as area under the concentration versus time curve from time zero (pre-dose) to the time of the last measurable concentration.
MTD/MAD is defined as the highest dose level at which less than 2 of 6 (or \< 33% if cohort is expanded beyond 6) participants experience a dose limiting toxicity.
Maximum observed concentration (Cmax)
| Arm | Type | Description |
|---|---|---|
| ABBV-399 | EXPERIMENTAL | ABBV-399 via intravenous administration at escalating dose levels. |
| Name | Type | Description |
|---|---|---|
| ABBV-399 | DRUG | Intravenous infusion |
Inclusion Criteria: * Participant with histologically confirmed advanced solid tumor. * Participant must have advanced solid tumor that is not amenable to surgical resection or other approved therapeutic options that have demonstrated clinical benefit. * Participant has an Eastern Cooperative Oncol...
ABBV-399 is an investigational small molecule being studied for the treatment of advanced solid tumors cancer. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities. The drug is being evaluated for its safety and pharmacokinetics in patients with advanced solid tumors.
ABBV-399 is being developed by AbbVie Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol ABBV. The company is conducting clinical trials to evaluate the drug's safety and pharmacokinetics in patients with advanced solid tumors.
ABBV-399 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The Phase 1 trial has been completed, and the drug remains in early-stage clinical development for advanced solid tumors cancer.
ABBV-399 has one completed Phase 1 clinical trial, identified as NCT03311477. This study evaluated the safety and pharmacokinetics of ABBV-399 in Japanese participants with solid tumors. The trial enrolled 9 participants and was conducted in Japan.
ABBV-399 is not FDA approved. It is an investigational drug currently in Phase 1 clinical development for advanced solid tumors cancer. The drug has completed a Phase 1 trial, but it remains under investigation and has not received regulatory approval.